Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer Print E-mail
By Staff and Wire Reports   
Monday, 16 November 2015 10:39
Cellceutix Corporation (OTC: CTIX), reports, based upon ongoing laboratory studies, the Company intends to use docetaxel for the combination therapy arm in the planned Phase 2 clinical trial to treat patients with platinum-resistance ovarian cancer. Cellceutix is designing the multi-arm study to evaluate Kevetrin as a monotherapy and as a component of combination therapy.
Read more...
 
FDA approves vaccine for Ebola clinical trials Print E-mail
By Ghana News Agency   
Sunday, 15 November 2015 15:32
The Food and Drugs Authority (FDA) has approved a vaccine, namely the Johnson Ebola vaccine for clinical trials as part of international effort to find a cure to deadly Ebola Virus Disease (EVD).  A second vaccine, the GSK vaccine, is currently being considered for approval.
Read more...
 
AstraZeneca’s potential $3 billion cancer pill wins early approval Print E-mail
By Ben Hirschler - REUTERS   
Saturday, 14 November 2015 03:45
A new lung cancer pill from AstraZeneca , designed for patients whose disease has worsened after treatment with other therapies, won early U.S. approval on Friday, in a boost for the British drugmaker.
Read more...
 
FT: Amgen in the hunt for a $10B biotech buyout Print E-mail
By John Carroll - FierceBiotech   
Tuesday, 10 November 2015 02:57
Amgen is jumping back into the M&A game. And it's looking for another Onyx-sized deal that can deliver a late-stage drug ready to be hustled across the finish line.
Read more...
 
FDA Approves New Once-a-Day HIV Pill Print E-mail
By CHERI CHENG - FDA News Today   
Saturday, 07 November 2015 17:51
The U.S. FDA has approved a new HIV pill that will make taking medications easier for HIV positive patients. The incurable infection, HIV (human immunodeficiency virus) leads to AIDS.    
Read more...
 
U.S. FDA Approves Gilead’s Single Tablet Regimen Genvoya® Print E-mail
By Staff and Wire Reports   
Thursday, 05 November 2015 22:30
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the first TAF-based regimen to receive FDA approval.
Read more...
 
Pfizer, Allergan Confirm Preliminary Merger Talks Print E-mail
By FDAnews Drug Daily Bulletin   
Thursday, 05 November 2015 11:37
Pfizer is in preliminary talks to purchase part or all of Irish drugmaker Allergan, the two companies confirmed last week.
Read more...
 
Actinium Pharma Further Strengthens Product Development Print E-mail
By Staff and Wire Reports   
Wednesday, 04 November 2015 14:47
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) announced the appointment of Dr. Xin Du, Ph.D., to the position of Executive Director, Regulatory Affairs and Dr. Sri Srivastava, Ph.D., PMP, to the position of Associate Director of Project Management.
Read more...
 
Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results Print E-mail
By Staff and Wire Reports   
Monday, 02 November 2015 21:59
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015.
Read more...
 
Big Lots BIG Seasonal Play Print E-mail
By Staff and Wire Reports   
Monday, 02 November 2015 08:53
In Monday’s Goldman Guide we reviewed the recent successes of some mega cap stocks. Bigger is better right now. Additionally, we mentioned the fact that year end seasonality usually favors small cap stocks. Finally, there is the holiday retail effect.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 56

Newsletter